Evidence map›Paper›PMID 32195221›Full record

ArticleFrontiers in chemistry2020

Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins.

Bianca Del B Sahm, Jade Peres, Paula Rezende-Teixeira, Evelyne A Santos, Paola C Branco, Anelize Bauermeister, Serah Kimani, Eduarda A Moreira, Renata Bisi-Alves, Claire Bellis and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Chromomycin AFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Bianca Del B SahmDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Jade PeresDivision of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa.
Paula Rezende-TeixeiraDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Evelyne A SantosDepartment of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Paola C BrancoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Anelize BauermeisterDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Serah KimaniDivision of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa.
Eduarda A MoreiraDepartment of Physics and Chemistry, School of Pharmaceutical Sciences, University of São Paulo, Ribeirao Preto, Brazil.
Renata Bisi-AlvesDepartment of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Claire BellisDivision of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa.
Mihlali MlazaDivision of Cell Biology, Department of Human Biology, University of Cape Town, Cape Town, South Africa.
Paula C JimenezDepartment of Sea Sciences, Federal University of São Paulo, Santos, Brazil.
Norberto P LopesDepartment of Physics and Chemistry, School of Pharmaceutical Sciences, University of São Paulo, Ribeirao Preto, Brazil.
Glaucia M Machado-SantelliDepartment of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Sharon PrinceDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Leticia V Costa-LotufoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRUniversity of Cape Town · ZAUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TBX2 transcription factor plays critical roles during embryonic development and it is overexpressed in several cancers, where it contributes to key oncogenic processes including the promotion of proliferation and bypass of senescence. Importantly, based on compelling biological evidences, TBX2 has been considered as a potential target for new anticancer therapies. There has therefore been a substantial interest to identify molecules with TBX2-modulatory activity, but no such substance has been found to date. Here, we adopt a targeted approach based on a reverse-affinity procedure to identify the ability of chromomycins A

Indexed as

chromomycinsDNA-binding agentsmelanomamicroscale thermophoresisreverse affinityT-box factors

Identifiers

PMID32195221
PMCPMC7062867
OpenAlexW3009889042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.